Fluidigm
Corporation (FLDM) is a life sciences company that develops and
markets innovative technologies and products for the analysis of
biological systems. The company's products and services are used in a
range of applications, including genomics research, single-cell
analysis, and clinical diagnostics. Fluidigm Corporation is
headquartered in South San Francisco, California.
Fluidigm
Corporation had a market capitalization of approximately $931 million.
The company's total revenue for the fiscal year 2020 was $147.8
million, representing an increase from $144.6 million in the previous
year. Net loss for the same period was $51.5 million, a decrease from
a net loss of $59.7 million in the previous year.
Fluidigm
Corporation's innovative technologies and products have enabled
researchers to gain deeper insights into biological systems, and have
contributed to advances in genomics research and personalized
medicine. The company has a strong intellectual property portfolio,
and has formed strategic partnerships with a range of organizations to
expand the reach of its products and services.
The life
sciences industry is subject to various risks, including regulatory
risks and competition from other companies. However, Fluidigm
Corporation's strong track record of innovation and strategic
partnerships should position it well for continued success in the
future.
Fluidigm Corporation's stock is listed on the NASDAQ
stock exchange under the ticker symbol FLDM. Investors should
carefully consider their investment objectives, risk tolerance, and
other factors before investing in Fluidigm Corporation or any other
life scienc
|
